Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer.
about
Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patientsFOLFOX chemotherapy can safely be given to neutropenic patients with early-stage colorectal cancer for higher dose intensity and fewer visits.Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study.Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies.FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases.
P2860
Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neutropenia and relative dose ...... val for resected colon cancer.
@en
type
label
Neutropenia and relative dose ...... val for resected colon cancer.
@en
prefLabel
Neutropenia and relative dose ...... val for resected colon cancer.
@en
P2093
P2860
P1476
Neutropenia and relative dose ...... val for resected colon cancer.
@en
P2093
Khodadad R Javaheri
Sharlene Gill
Yaling Yin
P2860
P2888
P304
P356
10.1007/S12029-014-9639-2
P577
2014-12-01T00:00:00Z